Item 2.02 Results of Operations and Financial Condition.
In connection with a proposed public offering of shares of common stock of
Reviva Pharmaceuticals Holdings, Inc. (the "Company"), the Company is disclosing
selected preliminary operating results for the quarter ended March 31, 2021 and
certain preliminary financial condition information as of March 31, 2021, as set
• Net operating loss for the three months ended March 31, 2021 is expected to be
approximately $1.9 million.
• A gain on remeasurement of warrant liability is expected to be recorded for
approximately $923,000, which will be included as other income, a non-operating
financial statement line item on the Company's statement of operations for the
three months ended March 31, 2021.
• Cash as of March 31, 2021 was approximately $5.6 million. If the Company does
not obtain additional financing, either through the completion of the proposed
public offering or via other financing alternatives, or the Company does not
prudently manage its expenses, its financial condition, cash flows and results
of operations could be materially and adversely affected.
The above information is preliminary financial information for the first quarter
of 2021 and subject to completion. The unaudited, estimated results for the
first quarter of 2021 are preliminary and were prepared by the Company's
management, based upon its estimates, a number of assumptions and currently
available information, and is subject to revision based upon, among other
things, quarter-end closing procedures and/or adjustments, the completion of the
Company's interim consolidated financial statements and other operational
procedures. This preliminary financial information is the responsibility of
management and has been prepared in good faith on a consistent basis with prior
periods. However, the Company has not completed its financial closing procedures
for the quarter ended March 31, 2021, and its actual results could be materially
different from the preliminary financial information, which preliminary
information should not be regarded as a representation by the Company or its
management as to the Company's actual results for quarter ended March 31, 2021.
In addition, Armanino LLP, the Company's independent registered public
accounting firm, has not audited, reviewed, compiled, or performed any
procedures with respect to this preliminary financial information and does not
express an opinion or any other form of assurance with respect to this
preliminary financial information. During the course of the preparation of the
financial statements and related notes as of and for the quarter ended March 31,
2021, the Company may identify items that would require the Company to make
material adjustments to this preliminary financial information. As a result,
prospective investors should exercise caution in relying on this information and
should not draw any inferences from this information. This preliminary financial
information should not be viewed as a substitute for full financial statements
prepared in accordance with United States generally accepted accounting
principles and reviewed by the Company's auditors.
The Company's financial statements and related notes as of and for the quarter
ended March 31, 2021 may not be filed with the SEC until after the proposed
public offering is completed. The Company expects to file its Quarterly Report
on Form 10-Q including its financial statements for the quarter ended March 31,
2021 on or about May 17, 2021.
The information furnished under this Item 2.02 shall not be considered "filed"
under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor
shall it be incorporated by reference into any future filing under the
Securities Act of 1933, as amended, or under the Exchange Act, unless the
Company expressly sets forth in such future filing that such information is to
be considered "filed" or incorporated by reference therein.
© Edgar Online, source Glimpses